Post-translational modifications of huntingtin's N17 region: implications for self-association and membrane binding亨廷蛋白N17区域的翻译后修饰：对自聚集和膜结合的影响biochimica et biophysica acta molecular basis of diseaseIF02025-08-180PRE
The therapeutic landscape of tauopathies: challenges and prospectsALZHEIMERS RESEARCH & THERAPYIF7.62023-10-0617OAAI
IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathwayLIFE SCIENCE ALLIANCEIF2.92023-08-083OA
Current directions in tau research: Highlights from Tau 2020ALZHEIMERS & DEMENTIAIF11.12021-09-2849OA
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82021-03-309PRE
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interactionBIOORGANIC & MEDICINAL CHEMISTRYIF32020-11-0119PRE
Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systemsJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92019-04-0125OAAI
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease ModelsJOURNAL OF MEDICINAL CHEMISTRYIF6.82019-03-0619PREAI
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICSIF32017-10-0151PREAI
Emerging β-Sheet Rich Conformations in Supercompact Huntingtin Exon-1 Mutant StructuresJOURNAL OF THE AMERICAN CHEMICAL SOCIETYIF15.62017-06-2336OAAI
OPTIMISATION OF POTENT, SELECTIVE AND BRAIN PENETRANT ATM INHIBITORS AS POTENTIAL THERAPEUTIC AGENTS FOR HDJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52016-09-130PREAI
AN OVERVIEW OF ENERGY METABOLISM IN HUNTINGTON'S DISEASE AS A THERAPEUTIC TARGETJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52016-09-130PREAI
The promise and peril of chemical probes (vol 11, pg 536, 2015)NATURE CHEMICAL BIOLOGYIF13.72015-10-207OAAI
Lead Optimization toward Proof-of-Concept Tools for Huntington's Disease within a 4-(1H-Pyrazol-4-yl)pyrimidine Class of Pan-JNK InhibitorsJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-03-1936PREAI
A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasmaJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12015-03-0112PREAI
Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington's DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-01-2359PREAI
CHDI-00340246, A KYNURENINE MONOOXYGENASE INHIBITOR AS POTENTIAL THERAPEUTIC AGENT FOR THE TREATMENT OF HUNTINGTON'S DISEASEJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52014-09-170PREAI
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's DiseaseACS MEDICINAL CHEMISTRY LETTERSIF42012-08-1323OAAI
Discovery and Structure-Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington's DiseaseJOURNAL OF MEDICINAL CHEMISTRYIF6.82012-01-2770PREAI
Frontal affinity chromatography with MS detection of EphB2 tyrosine kinase receptor. 2. Identification of small-molecule inhibitors via coupling with virtual screeningJOURNAL OF MEDICINAL CHEMISTRYIF6.82005-04-1243OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向